Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of AZD8931 Monotherapy and AZD8931 + Paclitaxel in Japanese Patients With Advanced Solid Tumors/Breast Cancer
jRCT2080220921Phase 1
- Sponsor
- AstraZeneca
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapitinib in Non-hematologic malignancy and breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Primary safety and tolerability of AZD8931.
02
Drugs
sapitinib
03
Conditions
Non-hematologic malignancybreast cancer
Beyond the preview
Go deeper on jRCT2080220921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220921.